Compare REFI & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFI | NKTX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.1M | 198.2M |
| IPO Year | 2021 | 2020 |
| Metric | REFI | NKTX |
|---|---|---|
| Price | $10.17 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 179.8K | ★ 790.6K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $17.47 | N/A |
| Revenue Next Year | $0.06 | N/A |
| P/E Ratio | $43.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.02 | $1.70 |
| 52 Week High | $14.57 | $3.72 |
| Indicator | REFI | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 34.58 |
| Support Level | N/A | $1.84 |
| Resistance Level | $12.41 | $2.32 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 16.30 | 4.36 |
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.